

05 September 2025

Domestic earnings should pick up, with a lag

 Multiple fiscal and monetary measures since the start of 2025 seek to keep domestic economy healthy as external environment turns hostile Girish Pai | Research Team research@bobcaps.in

- A shift from capex to consumption driven growth and within that a push towards a broad based one instead of a K-shaped one should be good for earnings of multiple sectors, more so in FY27
- While some stocks have moved +vely in response there are some one can still look at - Banks, Cement, Consumer durables and Insurance

Rationalization of GST one among many monetary and fiscal measures that will offset a harsh external environment: We believe it started with loosening of liquidity by the RBI in early 2025, easing of regulations including risk-weights, front loading of repo rate cuts (with another 25-50bps likely in the next 6 months), lowering of the CRR, Rs1trn tax give away and GST rate rationalization announced on 3 September 2025. These, combined with lower inflation, transmission of lower interest rates and 8th pay commission award, which is likely over the next 12-24 months, will drive domestic growth. While many of these were not specifically planned for it, they have all come together in a reinforcing fashion to offset likely softness in demand due to the first and second order impact of higher Tariffs imposed by US not just on India but also on other countries. GST Council announced a new two rate structure – 5% and 18% with special rate of 40% for sin and luxury goods and removed the 12% and 28% rates. The new GST rates are applicable from 22 September 2025.

See mixed earnings picture in 2HFY26 but should see material revival in FY27: We think a combination of weak NIMs (with likely further cuts to repo rates in 2HFY26) and lower treasury income (due to higher Gsec yields) should lead to downgrade of earnings for the banks in FY26. This could be offset to some extent by higher earnings by some domestic sectors. But we think the cumulative impact of all of these should

lead to possibly mid-teen or higher earnings growth in FY27

Some stocks are already reflecting the potential support or upturn in earnings but others are not: Fig 1 indicates the price performance of NSE 100 stocks CYTD, MTD, Since 14 August (GST rate rationalization was announced) and 4 September 2025 (post official announcement GST rate rationalization). This shows that Auto OEM stocks have reacted +vely to the various monetary and fiscal measures and so did some of the NBFCs. The life Insurance companies have also likely reacted to easing of regulatory pressure that they saw in 2024. However, Banks (because of near term earnings pressure), consumer (staples and discretionary) companies, cement, consumer durable and even insurance firms have not responded adequately to the likely pick-up in demand/earnings in 2HFY26/FY27.





Fig 1 – Performance of Nifty – 100 index stocks

		Holding Period Returns (%)				
Ticker	Name	CYTD	1 Month	Since 14 August	04-Sep	
ABB IS Equity	ABB India Ltd	(24.3)	2.1	3.1	(0.5)	
ACEM IS Equity	Ambuja Cements Ltd	7.5	(5.2)	(0.7)	(1.1)	
ADANI IS Equity	Adani Power Ltd	15.1	4.3	4.3	(0.1)	
ADANIENS IS Equity	Adani Energy Solutions Ltd	(5.3)	(4.5)	(1.6)	(0.7)	
ADANIGR IS Equity	Adani Green Energy Ltd	(10.1)	(5.5)	2.0	(0.7)	
ADE IS Equity	Adani Enterprises Ltd	(9.4) 8.8	(3.2)	0.3	(0.4)	
ADSEZ IS Equity	Adani Ports & Special Economic Zone Ltd		(4.1)	2.5		
APHS IS Equity	Apollo Hospitals Enterprise Ltd	6.3	6.0	(1.0)	2.1	
APNT IS Equity	Asian Paints Ltd	13.0	4.2	1.0	0.6	
AXSB IS Equity	Axis Bank Ltd	(0.9)	(1.3)	(1.3)	(0.4)	
BAF IS Equity	Bajaj Finance Ltd	32.2	1.2	4.0	4.3	
BAJAJHFL IS Equity	Bajaj Housing Finance Ltd	(11.2)	(0.8)	0.4	(1.1)	
BHARTI IS Equity	Bharti Airtel Ltd	19.7	(1.6)	0.5	(0.2)	
BHE IS Equity	Bharat Electronics Ltd	30.2	(2.6)	(1.6)	(1.6)	
BJAUT IS Equity	Bajaj Auto Ltd	6.2	11.3	11.0	(0.5)	
BJFIN IS Equity	Bajaj Finserv Ltd	25.4	1.7	2.1	1.8	
BJHI IS Equity	Bajaj Holdings & Investment Ltd	9.8	(6.3)	(7.9)	(0.3)	
	Bank of Baroda	2.5				
BOB IS Equity		2.5	(1.1)	(1.8)	(1.9)	
BOS IS Equity	Bosch Ltd		(0.0)		(0.9)	
BPCL IS Equity	Bharat Petroleum Corp Ltd	11.4	(0.9)	(1.0)	(0.6)	
BRIT IS Equity	Britannia Industries Ltd	25.7	2.1	11.4	3.0	
CBK IS Equity	Canara Bank	12.1	0.5	(0.9)	(2.1)	
CGPOWER IS Equity	CG Power & Industrial Solutions Ltd	0.9	10.7	10.1	0.9	
CIFC IS Equity	Cholamandalam Investment and Finance Co Ltd	21.6	(2.2)	(1.5)	1.5	
CIPLA IS Equity	Cipla Ltd/India	4.3	4.2	0.9	(0.0)	
COAL IS Equity	Coal India Ltd	5.8	7.0	2.8	0.4	
DABUR IS Equity	Dabur India Ltd	8.3	2.6	8.5	1.7	
DIVI IS Equity	Divi's Laboratories Ltd	1.5	(5.0)	0.5	(0.5)	
DLFU IS Equity	DLF Ltd	(6.6)	(3.6)	1.7	(8.0)	
DMART IS Equity	Avenue Supermarts Ltd	33.6	13.4	9.2	1.5	
DRRD IS Equity	Dr Reddy's Laboratories Ltd	(8.5)	3.0	0.1	(0.7)	
EIM IS Equity	Eicher Motors Ltd	33.8	13.4	10.5	0.8	
ETERNAL IS Equity	Eternal Ltd	17.3	6.8	2.4	0.0	
GAIL IS Equity	GAIL India Ltd	(2.7)	2.0	2.4	(1.9)	
GCPL IS Equity	Godrej Consumer Products Ltd	19.4	2.5	7.6	(2.4)	
GRASIM IS Equity	Grasim Industries Ltd	14.3	0.1	0.6	1.0	
HAVL IS Equity	Havells India Ltd	(5.9)	3.8	5.9	1.2	
HCLT IS Equity	HCL Technologies Ltd	(21.3)	(0.6)	(1.6)	(1.6)	
HDFCB IS Equity	HDFC Bank Ltd	9.1	(4.2)	(4.1)	0.7	
HDFCLIFE IS Equity	HDFC Life Insurance Co Ltd	26.2	5.0	(1.6)	(2.9)	
HMCL IS Equity	Hero MotoCorp Ltd	33.8	17.9	13.6	0.0	
HNAL IS Equity	Hindustan Aeronautics Ltd	7.7	(1.6)	(2.0)	(0.3)	
HNDL IS Equity	Hindalco Industries Ltd	24.2	8.8	6.9	(0.5)	
HUVR IS Equity	Hindustan Unilever Ltd	15.7	4.8	7.4	0.1	
HYUNDAI IS Equity	Hyundai Motor India Ltd	40.6	16.0	12.2	(1.4)	
ICICIBC IS Equity	ICICI Bank Ltd	9.8	(3.8)	(2.1)	0.6	
ICICIGI IS Equity	ICICI Lombard General Insurance Co Ltd	2.3	(3.9)	(4.0)	2.7	
IH IS Equity	Indian Hotels Co Ltd/The	(11.5)	3.4	(0.1)	0.1	
IIB IS Equity	Industrioles Co Eta/Trie	(20.0)	(4.5)	(0.1)	(1.7)	
INDIGO IS Equity	InterGlobe Aviation Ltd	26.2	(0.5)	(4.4)	(0.8)	
INFO IS Equity	Infosys Ltd	(20.2)	(0.5)	2.2	(1.1)	
II O IO Equity	iiilooyo Liu	(20.2)	(0.1)	۷.۷	(1.1)	



		Holding Period Returns (%)				
Ticker	Name	CYTD	1 Month	Since 14 August	04-Sep	
INFOE IS Equity	Info Edge India Ltd	(21.1)	(0.3)	0.1	(2.5)	
IOCL IS Equity	Indian Oil Corp Ltd	5.2	0.8	0.3	(0.6)	
IPRU IS Equity	ICICI Prudential Life Insurance Co Ltd	(6.8)	(0.4)	(2.8)	(1.6)	
IRFC IS Equity	Indian Railway Finance Corp Ltd	(16.6)	(4.7)	(0.7)	(1.6)	
ITC IS Equity	ITC Ltd	(6.9)	(1.2)	0.1	1.0	
JINDALST IS Equity	Jindal Steel Ltd	10.7	5.1	5.6	0.3	
JIOFIN IS Equity	Jio Financial Services Ltd	5.2	(5.9)	(4.2)	(1.4)	
JSTL IS Equity	JSW Steel Ltd	19.3	1.5	2.6	0.0	
JSW IS Equity	JSW Energy Ltd	(20.5)	(5.3)	(3.8)	(1.3)	
KMB IS Equity	Kotak Mahindra Bank Ltd	9.9	(1.8)	(0.9)	(0.5)	
LICI IS Equity	Life Insurance Corp of India	(1.1)	(2.7)	(1.9)	0.8	
LODHA IS Equity	Lodha Developers Ltd	(13.2)	(3.1)	(2.1)	(0.8)	
LT IS Equity	Larsen & Toubro Ltd	0.7	(0.8)	(2.1)	(0.2)	
LTIM IS Equity	LTIMindtree Ltd	(6.2)	2.0	1.6	0.4	
MM IS Equity	Mahindra & Mahindra Ltd	10.1	2.7	0.6	5.9	
MOTHERSO IS Equity	Samvardhana Motherson International Ltd	(6.7)	(1.8)	3.7	(2.3)	
MSIL IS Equity	Maruti Suzuki India Ltd	39.0	20.7	15.4	(1.8)	
NEST IS Equity	Nestle India Ltd	11.3	4.9	9.7	1.5	
NTPC IS Equity	NTPC Ltd	1.0	0.7	(1.5)	(0.3)	
ONGC IS Equity	Oil & Natural Gas Corp Ltd	1.9	1.8	0.9	(0.9)	
PIDI IS Equity	Pidilite Industries Ltd	8.2	5.8	0.9	0.2	
PNB IS Equity	Punjab National Bank	4.3	(0.3)	(1.9)	(0.8)	
POWF IS Equity	Power Finance Corp Ltd	(9.2)	(3.8)	(4.5)	(1.1)	
PWGR IS Equity	Power Grid Corp of India Ltd	(5.8)	(0.2)	(0.5)	(1.5)	
RECL IS Equity	REC Ltd	(23.7)	(5.9)	(3.6)	(1.0)	
RELIANCE IS Equity	Reliance Industries Ltd	13.4	(2.4)	(0.1)	(1.0)	
SBILIFE IS Equity	SBI Life Insurance Co Ltd	30.5	(1.1)	(1.6)	(1.1)	
SBIN IS Equity	State Bank of India	4.2	2.1	(1.7)	(0.3)	
SHFL IS Equity	Shriram Finance Ltd	2.4	(6.2)	(4.9)	(0.1)	
SIEM IS Equity	Siemens Ltd	(1.0)	7.3	1.4	(1.8)	
SRCM IS Equity	Shree Cement Ltd	17.0	(2.3)	(1.5)	0.0	
SUNP IS Equity	Sun Pharmaceutical Industries Ltd	(15.5)	(3.8)	(3.8)	0.2	
SWIGGY IS Equity	Swiggy Ltd	(20.4)	7.9	8.1	(1.7)	
TATA IS Equity	Tata Steel Ltd	24.4	5.2	8.1	(0.6)	
TATACONS IS Equity	Tata Consumer Products Ltd	21.6	3.0	5.1	(3.0)	
TCS IS Equity	Tata Consultancy Services Ltd	(22.0)	0.8	2.5	(0.1)	
TECHM IS Equity	Tech Mahindra Ltd	(10.0)	2.3	1.4	(0.5)	
TPWR IS Equity	Tata Power Co Ltd/The	(0.3)	0.5	1.0	(1.7)	
TRENT IS Equity	Trent Ltd	(23.0)	4.4	2.0	0.9	
TRP IS Equity	Torrent Pharmaceuticals Ltd	8.4	(0.2)	(0.4)	(0.2)	
TTAN IS Equity	Titan Co Ltd	13.8	10.0	5.8	0.0	
TTMT IS Equity	Tata Motors Ltd	(5.7)	5.9	4.1		
	TVS Motor Co Ltd	44.2	15.6	12.6	(0.7)	
TVSL IS Equity			0.6	2.1		
UNITDSPR IS Equity	United Spirits Ltd	(16.4) 12.1	3.9	3.4	(1.9)	
UTCEM IS Equity	UltraTech Cement Ltd				(0.6)	
VBL IS Equity	Varun Beverages Ltd	(20.6)	(0.7)	0.7	(3.1)	
VEDL IS Equity	Vedanta Ltd	4.2	5.7	6.0	(0.9)	
WPRO IS Equity	Wipro Ltd	(14.0)	1.4	1.1	(1.8)	
ZYDUSLIF IS Equity	Zydus Lifesciences Ltd urch Note: Returns till 3 September 2025	4.9	5.1	2.0	0.4	

Source: Company, BOBCAPS Research | Note: Returns till 3 September 2025



Fig 2 – Sectoral announcements and impact

Sector	Previous Rate	Current Rate	Impact	Other Notes	
Pharma: All Drugs and medicines intended for personal use	12%	5%	Beneficial for companies like Sun, Alkem, Cipla, Mankind, Abbott etc. who are domestic focused and have MR count of 8000-12000. Abbott is the second largest company in the IPM with MR count of ~3500		
Pharma: life saving drugs used for treatment of cancer and rare diseases	12%/ 5%	0%	Reduction of GST on life saving drugs used for treatment of cancer and rare diseases. 33 lifesaving drugs GST reduced from 12% to 0% (Onasemnogene abeparvovec, Asciminib, Mepolizumab,Pegylated Liposomal Irinotecan, Daratumumab, Teclistamab, Amivantamab, Obinutuzumab etc.) and Reduction of GST from 5% to 0% on 3 lifesaving drugs (Agalsidase Beta, Imiglucerase, Eptacog alfa activated recombinant coagulation factor VIIa). Beneficial for companies like Astrazeneca, Alkem, Biocon who have biosimilars launched in the Indian market.	Our view – reduction of GST rates across drugs from 12% to 5% is a positive for the sector as it will push volume growth in the IPM which is currently at 1-1.5%. However, the domestic region sales growth for our coverage companies is likely to be 100-150 bps above the IPM growth of 7-9%. However, India region contribution to the sector is ~33% which would not have meaningful impact at the blended level, therefore we do not revise our estimates.	
FMCG (Packaged foods)	12%	5%	Packaged foods GST is cut from 12% to 5% while personal care GST is cut from 18% to 5%. For FMCG, this implies a ~8-10% reduction retail price reduction on biscuits, noodles, dairy, chocolates, shampoos, soaps, oral care, homecare. Volume uplift will depend on the pass through of lower GST in retail prices. The reform improves affordability, supports market penetration, and drives demand across general trade, modern trade, and quick commerce platforms. Foods Portfolio Britannia, Nestlé India, Tata Consumer, ITC are key beneficiaries of the GST cut to 5%. with large exposure to biscuits, noodles, packaged staples, dairy, butter and ghee. Britannia and Nestle see the highest impacts. Tata Consumer gains in coffee and staples; ITC benefits in biscuits, snacks and dairy.	Risks & United Breweries Retail price changes considerably depends on companies balancing margins / volumes resulting in pass-through and MRP resets along with the government's execution on pricing audits. Companies may stagger cuts through grammage adjustments to defend gross margins. United Breweries is unaffected as alcohol remains outside GST. ITC's cigarette business is outside GST, tentatively until December 2025, post which it would attain the 40% slab, in line with sin goods. Key risk is muted premiumisation if companies over-pass benefits. Overall, reform is consumption-accretive, setting up FY26 as a strong demand year.	
FMCG (Personal care)	18%	5%	Personal & Healthcare HUL, Godrej Consumer, Dabur, and Marico gain from the GST cut to 5% in shampoos, soaps, hair oils, oral care, and select nutrition products driving retail price relief. HUL (personal + home care) and Godrej (again home+personal care) have tailwinds. Dabur benefits in oral care, hair oils while Marico in hair oil, cosmetics, vitamins / supplements.	- _J ou	
Banks				The GST rate cut is expected to improve credit growth for the banking sector. The banking sector had outstanding loans in personal loans segment (retail loans) of Rs 61.6 trn (+11.9% YoY) as of July 2025. Personal loans segment mainly includes housing, vehicle, credit cards,	



Sector	Previous Rate	Current Rate	Impact	Other Notes
		-		education among others. This segment accounted for ~33% of total non-food credit outstanding at the industry level as of July 2025. Of which, the housing remains the largest segment at Rs 30.8trn as of July 2025. The GST rate cut in the building materials is expected to reduce construction costs and may support the demand for housing as well as affordable housing segments. In addition, the GST rate cut in the vehicle segment (Rs 6.4tm outstanding credit) is likely to improve the credit demand for non-luxury vehicles. We note that retail focused banks such as ICICI, HDFCB, Kotak, Axis and SBI to benefit in terms of higher credit growth. Overall, the banking sector is expected to witness a second order impact due to GST rate cut.
				Mixed - ITC would be no longer available, hence pass through would be difficult/ incomplete.
				There can be a volume game, while there would be a meaningful reduction in the premiums for the policyholders, prospective policyholders demand may increase with the prices (premiums) becoming now affordable.
Exemption on GST on Individual Life	18%	Individual: Nil (Exempted)	HDFC LifeSBI LifeICICI Pru Life	Further, there could be challenges in terms of policies purchased before two to three months or one month, as these may be withdrawn on account of lower future premiums. There could be delay in the purchases until the rate cut gets implemented/effective ie. 22nd Sep.
and Health Insurance to Nil		Group: 18%	• LICI	In case, the companies decide not to pass the cost and take the entire hit on their books, then the ITC hit of ~5% would be there. It has to be noted that the ensuing policies particularly the protection would see better demand with higher sum assured and hence would aid margins as these products carry higher VNB margins. However, the back book which was priced considering the ITC credit would impact EV of companies going forward.
				Hence, the VNB margins may get impacted in the medium term if price hikes are not undertaken to offset the rate cut.
			 Bajaj Finance 	Positive - GST rate rationalization is expected to serve as a significant demand catalyst, particularly for consumption-driven and price-sensitive sectors. Lower taxes would aid consumption demand, thereby supporting credit growth.
				A cut in the GST rate on consumer durables would have a twofold impact: demand revival and margin dynamics.
Consumer Durables				On the demand side, lower effective prices could stimulate discretionary spending, especially in price-sensitive categories like entry-level refrigerators, washing machines and Acs thereby aiding volume recovery in a weak consumption environment. The benefit is typically more pronounced in mid-tier products where affordability drives penetration. On the margin front, companies may choose to pass on the full tax benefit to consumers to gain market share, hence we don't see any improvement in margin in near term. However, over the medium term, sustained demand elasticity from lower prices could improve operating leverage for manufacturers and distributors, but the overall impact will hinge on demand recovery in rural which is still under pressure—how it responds to the lower price points.
Cement	28%	18%		The decision, announced after the 56th GST Council meeting, is expected to reduce cement prices by Rs 10–40 per 50kg bag (assuming cement bag prices at Rs350-450 range), offering relief to homebuyers, real estate developers, and infrastructure firms.



Sector	Previous Rate	Current Rate	Impact	Other Notes
				Real estate developers stand to benefit from improved project viability, while infrastructure projects under schemes like PM Awas Yojana and Bharatmala gain cost efficiencies. However, the cement industry will be indifferent from margins or earnings perspective as the industry will pass on tax savings to consumers amid scrutiny from the Competition Commission of India and Government tax authorities.
				Despite the price drop, cement demand is not expected to increase significantly in the short term due to fixed construction cycles, inelastic demand and cement's perishable nature, limiting stockpiling. While immediate consumption may not surge, the lower costs could shift consumer preference toward premium, branded cement products, boosting market share for established players. The move also helps curb inflation in building materials.
				The long-term outlook is positive, with potential demand growth in H2FY26 as infrastructure spending ramps up. However, challenges like rising input costs (e.g., limestone, coal) and monsoon-related delays could temper benefits.
				We continue our BUY rating on Ultratech Cement and Star Cement.
				The tax cut is expected to reduce on-road prices by 6–8% for small cars and two-wheelers, translating to savings of Rs 30–80k for models like Maruti WagonR, Baleno, Dzire, Tata Tiago, and Hyundai Grand i10, and Rs 6–10k for 2W like Honda Shine, Bajaj Pulsar, and Hero Splendor. Compact SUVs under 4m with sub-1200cc petrol engines, such as Tata Nexon, Hyundai Venue, Kia Sonet, and Mahindra XUV 3XO, are poised to see the most significant demand boost due to their popularity and price sensitivity. It could positively affect EMIs for these models, enhancing affordability for first-time buyers and rural households. Larger SUVs like Hyundai Creta and Mahindra XUV700 may see price reductions of Rs 40–130k, as the elimination of the 1–22% cess offsets the new 40% slab, and the uniform 18% tax slab for all the auto part through the value chain though savings are less pronounced.
Automobile				3W like Bajaj RE and Mahindra Treo is expected to get cheaper by Rs 5-15k boosting affordability for commercial operators. 3W sales, tied to last-mile transport, could see a 5–7% uptick, per ICRA, driven by lower costs and festive demand. Tractors are expected to decline in prices by Rs 10-20k.
				The tax changes create a mixed outlook for fuel types. Diesel vehicles, often larger models, and luxury cars face the 40% slab with no significant relief, widening the cost gap with petrol and CNG vehicles, which could accelerate their declining market share (diesel adoption has dropped steadily in India). EVs remain at a 5% GST rate, but the reduced tax differential with ICE vehicles (from 23% to 13%) may slow EV uptake, particularly for price-sensitive 2W and entry-level cars, where EVs' higher upfront costs are a barrier. Hybrid vehicles face mixed outcomes: small hybrids benefit from the 18% slab, while larger hybrids (e.g., Maruti Grand Vitara) fall under 40%, potentially dampening their appeal compared to EVs.

Source: Company, BOBCAPS Research



Fig 3 – Price Impact Across Automobile Segments

Segment	Models Examples	Pre-GST Rate	Post-GST Rate	Est. Price Drop (Rs)	Est. EMI Drop (Rs/mo)
Small Cars (<4m)	Maruti WagonR, Tata Tiago, Hyundai i10	28% + 1–3% cess	18%	30,000–80,000	1,000–2,000
Compact SUVs (<4m, <1200cc petrol)	Tata Nexon, Hyundai Venue, Kia Sonet	28% + 1–3% cess	18%	30,000–80,000	1,000–2,000
Large SUVs (>4m)	Hyundai Creta, Mahindra XUV700	28% + 15–22% cess	40%	40,000–1,30,000	1,500–2,000
Two-Wheelers (≤350cc)	Honda Shine, Bajaj Pulsar, Hero Splendor	28%–31%	18%	6,000–10,000	300–500
Three-Wheelers	Bajaj RE, Mahindra Treo	28%	18%	5,000-15,000	200-400
Tractors	Mahindra 575	12%	5%	10,000-20,000	300-600
Luxury Cars & Large Hybrids	Mercedes E-Class, Toyota Camry	28% + 15–22% cess	40%	Marginal or none	Negligible
Motorcycles (>350cc)	Classic 650, Harley Davidson	28% + 3% cess	40%	None or increase	None or increase
Electric Vehicles	Tata Harrier EV, Mahindra XEV 9e	5%	5%	Unchanged	Unchanged

Source: Company, BOBCAPS Research



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: BOB Capital Markets Limited

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: BOBCAPS

Trade Name: www.barodaetrade.com CIN: U65999MH1996GOI098009



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.



Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.